Rational Design of Cannabinoid-Containing Complex Mixtures (CCCMTM) for Disease-Targeted Therapies

To discover novel, disease-specific therapies, GBS utilizes rational design principles in creating Cannabinoid-Containing Complex Mixtures (CCCMTM) targeting the endocannabinoid system. GBS incorporates data from high throughput experiments using disease-specific cell and animal models that are combined with computer models of cannabinoid-sensitive receptor interactions in a predictive network pharmacology-based algorithm. The bioavailability of GBS’ Cannabinoid-Containing Complex Mixtures (CCCMTM) is enhanced using patent-protected, oral delivery systems including: a. oral dissolving tablets, b. time-released nanoparticles for oral administration, c. oral thin films, and d. gel capsules. Using an animal model of the disease, Proof of Concept has been established for GBS’ Parkinson’s disease therapy and the Mechanism of Action is being further explored. At the NRC Canada, GBS’ Parkinson’s Disease CCCM™ achieved the statistically-significant reduction of Parkinson’s- like symptoms in an animal model of the disease. Additionally, GBS’ neuropathic pain formulations look promising in animal studies. These important preclinical results will be included in GBS’ Investigational New Drug (IND) applications with US FDA in order to enter human clinical trial as soon as possible.